NEW STUDY: Joint Health Study with Natreon’s AyuFlex® (Terminalia chebula) Improves Joint Mobility, Comfort, and Functional Capacity in Healthy Overweight Subjects
New Brunswick, NJ, October 17th, 2017 – Natreon’s AyuFlex®, a clinically studied and standardized aqueous extract of Terminalia chebula, significantly improved joint mobility, comfort, and functional capacity in healthy overweight subjects according to a study recently published in BMC Complementary and Alternative Medicine (Lopez et al). AyuFlex® is a potent antioxidant and previous studies have noted the efficacy of AyuFlex® for modulating inflammation and oxidative stress.
This study, conducted at The Center for Applied Health Sciences in Ohio, was a 14-week, randomized, double blind, placebo-controlled study in 105 healthy overweight men and women (ages 35-70) with knee discomfort associated with exercise. Subjects were randomized to receive AyuFlex® 500 mg/day, AyuFlex® 1000 mg/day, or placebo. AyuFlex® supplementation resulted in significant improvements in mWOMAC scores, distance covered in the 6-minute walk test, and various VAS subscales. A significant reduction of cartilage oligomeric matrix protein (COMP) was observed in the AyuFlex® 500 mg/day group relative to placebo. This is a biochemical marker of connective tissue integrity and cartilage matrix turnover. This finding is consistent with a decrease in the net degradation of joint cartilage matrix molecules. Data from this study also suggest that the benefits of AyuFlex® may extend beyond knee joints to include overall/whole-body joint and spine health.
“Natreon is centered on the idea of ‘trusted science, naturally’ and our investment in clinical research demonstrates our commitment to this ideal. The positive results from the most recent AyuFlex® study deliver on consumer preference for natural and scientifically studied ingredients. We are excited by the opportunities ahead for AyuFlex® and our customers, as the market continues to seek botanical products backed by science,” stated Bruce Brown, President, Natreon, Inc.
“This study represents a thorough effort to explore the potential of AyuFlex (aqueous extract of Terminalia chebula) dietary supplementation to augment joint health and function in a healthy population. The study design included a randomized, placebo-controlled trial with placebo lead-in period, rigorous exclusion / inclusion criteria, validated outcome measures and markers of joint health, mobility and functional capacity and was well powered with N=105 and 2 dose groups. Taken together, these parameters lead to high-quality, reliable and clean data that can be interpreted with substantial validity. Natreon should be commended for the considerable investment in such science that provide brands, consumers, healthcare providers and all stakeholders with reliable data to make evidence-based dietary supplement recommendations.” –
Hector L. Lopez, M.D., CSCS, FAAPMR, FISSN,
Chief Medical Officer and Partner, The Center for Applied Health Sciences, LLC.
Co-Founder- Supplement Safety Solutions, LLC.
For more information on AyuFlex® or Natreon’s full portfolio of ingredients, please email email@example.com.
About Natreon, Inc.
Natreon Inc. is a 19 year old company located in New Jersey with a state of the art R&D facility in Kolkata, India, and is focused on developing and marketing Ayurvedic products backed by extensive research, high degree of standardization, multiple clinical studies, safety studies, and intellectual property. Natreon’s R&D team is headed by Prof. Shibnath Ghosal, a Fulbright scholar and an eminent natural product chemist with hundreds of publications in scientific journals and a group of Ph.D. and Master’s level scientists. Natreon’s scientific research includes process optimization, development of chromatographic analytical methods such as HPLC, HPTLC, GC-MS and LC-MS for standardization, development of marker compounds, and pharmacological studies. Safety studies are done in the USA and clinical studies are conducted in reputed institutes in India as well as the USA.